INTREXON CORPORATION (NYSE:XON) Files An 8-K Regulation FD DisclosureItem 7.01
On January8, 2018, ActoBio Therapeutics, Inc., a wholly-owned subsidiary of Intrexon Corporation, will deliver a presentation at the Biotech Showcase 2018 Conference in San Francisco, California. The slides to be used during the presentation are furnished herewith as Exhibit 99.1 and are incorporated by reference into Item 7.01 of this Current Report on Form 8-K.
As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 and the exhibit furnished hereunder will not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, nor will they be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as will be expressly set forth by specific reference in such a filing.
|Item 7.01||Financial Statements and Exhibits.|
INTREXON CORP ExhibitEX-99.1 2 d511494dex991.htm EX-99.1 EX-99.1 ActoBio Therapeutics™,…To view the full exhibit click
About INTREXON CORPORATION (NYSE:XON)
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.